Over-expression of angiotensin-converting enzyme (CD 143) on leukemic blasts as a clue for the activated local bone marrow RAS in AML

References

• Haznedaroglu I C, Tuncer S, Gursoy M. A local renin-angiotensin system in the bone marrow. Medical Hypotheses 1996; 46: 507–510
   PubMed Web of Science ®Google Scholar
• Haznedaroglu I C. A local renin-angiotensin system in the bone marrow still awaits its Christopher Columbus. Experimental Hematology 1998; 26: 279
   Web of Science ®Google Scholar
• Boranic M. While waiting for Christopher Columbus to discover alternative route(s) of bone marrow regulation, keep faith the body is a global system. Experimental Hematology 1998; 26: 1018–1019
   PubMed Web of Science ®Google Scholar
• Vasku A, Holla L, Znojil V. The best model of a cat is a cat, especially the same cat. Experimental Hematology 1999; 27: 187–188
   PubMed Web of Science ®Google Scholar
• Haznedaroglu I C. A local renin-angiotensin system in the bone marrow: hypothesis and clues. Experimental Hematology 1999; 27: 186–187
   PubMed Web of Science ®Google Scholar
• Haznedaroglu I C, Ozturk M A. Towards the understanding of the local hematopoietic bone marrow renin-angiotensin system. International Journal of Biochemical Cell Biology 2003; 35: 867–880
   PubMed Web of Science ®Google Scholar
• Strawn W B, Richmond R S, Ann T E, Gallagher P E, Ferrario C M. Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells. British Journal of Haematology 2004; 126: 120–126
   PubMed Web of Science ®Google Scholar
• Rodgers K E, Xiong S, Steer R, diZerega G S. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells 2000; 18: 287–294
   PubMed Web of Science ®Google Scholar
• Brunet dlG, Ivanovic Z, Leprivey-Lorgeot V, Praloran V. Angiotensin II that reduces the colony-forming ability of hematopoietic progenitors in serum free medium has an inverse effect in serum-supplemented medium. Stem Cells 2002; 20: 269–271
   PubMed Web of Science ®Google Scholar
• Peng C, Li W M, Ma Y P, Hu Z B, Cheng F J, Liu L B. Effect of angiotensin II on cord blood CD34(+) cells expansion in vitro. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2003; 11: 227–229
   PubMedGoogle Scholar
• Goker H, Haznedaroglu I C, Beyazit Y, Aksu S, Tuncer S, Misirlioglu M. Local umbilical cord blood renin-angiotensin system. Annals of Hematology 2005; 84: 277–281
   PubMed Web of Science ®Google Scholar
• Richmond R S, Tallant E A, Gallagher P E, Ferrario C M, Strawn W B. Angiotensin II stimulates arachidonic acid release from bone marrow stromal cells. Journal of Renin & Angiotensin Aldosterone Systems 2004; 5: 176–182
   PubMed Web of Science ®Google Scholar
• Abali H, Haznedaroglu I C, Goker H, Celik I, Ozatli D, Koray Z, et al. Circulating and local bone marrow renin-angiotensin system in leukemic hematopoiesis: preliminary evidences. Hematology 2002; 7: 75–82
   PubMedGoogle Scholar
• Wulf G G, Jahns-Streubel G, Nobiling R, Strutz F, Hemmerlein B, Hiddemann W, et al. Renin in acute myeloid leukaemia blasts. British Journal of Haematology 1998; 100: 335–337
   PubMed Web of Science ®Google Scholar
• Wulf G G, Jahns-Streubel G, Strutz F, Basenau D, Hufner M, Buske C. Paraneoplastic hypokalemia in acute myeloid leukemia: a case of renin activity in AML blast cells. Annals of Hematology 1996; 73: 139–141
   PubMed Web of Science ®Google Scholar
• Teresa Gomez Casares M, de la Igesia S, Perera M, Lemes A, Campo C, Gonzalez San Miguel J D. Renin expression in hematological malignancies and its role in the regulation of hematopoiesis. Leukemia & Lymphoma 2002; 43: 2377–2381
   PubMed Web of Science ®Google Scholar
• Pinto R P, Wang K K, Khoury H, Schimmer A D, Minden M D. Aberrant expression of angiotensin in acute myeloid leukemia. Blood 2004; 102: 2124A
   Google Scholar
• Montgomery H, Humphries S E, Leung P S. Renin-angiotensin systems: the new frontier. The International Journal of Biochemistry & Cell Biology 2003; 35: 758
   Web of Science ®Google Scholar
• Abali H, Gullu I H, Engin H, Haznedaroglu I C, Erman M, Tekuzman G. Old antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Medical Hypotheses 2002; 59: 344–348
   PubMed Web of Science ®Google Scholar
• Ozturk M A, Guven G S, Haznedaroglu I C. How hematopoietic stem cells know and act in cardiac microenvironment for stem cell plasticity? Impact of local renin-angiotensin systems. Medical Hypotheses 2004; 63: 866–874
   PubMed Web of Science ®Google Scholar
• Danilov S M, Sadovnikova E, Scharenborg N, Balyasnikova I V, Svinareva D A, Semikina E L, et al. Angiotensin-converting enzyme (CD143) is abundantly expressed by dendritic cells and discriminates human monocyte-derived dendritic cells from acute myeloid leukemia-derived dendritic cells. Experimental Hematology 2003; 31: 1301–1309
   PubMed Web of Science ®Google Scholar
• Hajek D, Tomiska M, Krahulcova E, Druckmuller M, Florianova M, Izakovicova-Holla L, et al. I/D ACE gene polymorphism in survival of leukemia patients—hypothesis and pilot study. Medical Hypotheses 2003; 61: 80–85
   PubMed Web of Science ®Google Scholar
• Rodgers K E, Xiong S, Steer R, diZerega G S. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells 2000; 18: 287–294
   PubMed Web of Science ®Google Scholar
• Haznedaroglu I, Tokgozoglu L, Caglar M, Kes S. Local cardiac renin-angiotensin system and hypertensive heart disease. Hypertension 1994; 24: 816–818
   PubMed Web of Science ®Google Scholar
• Haznedaroglu I C. Angiotensin I-converting enzyme, blood groups, and a local marrow-specific renin-angiotensin system. Experimental Hematology 1997; 25: 93
   PubMed Web of Science ®Google Scholar
• Cobankara V, Ozturk M A, Kiraz S, Ertenli I, Haznedaroglu I C, Pay S, et al. Renin and angiotensin-converting enzyme (ACE) as active components of the local synovial renin-angiotensin system in rheumatoid arthritis. Rheumatology International 2005; 25: 285–291
   PubMed Web of Science ®Google Scholar
• Nobuhiko A, Suganuma E, Babaev V R, Fogo A, Swift L L, Linton M F, et al. Angiotensin II amplifies macrophage-driven atherosclerosis. Arteriosclerosis & Thrombosis Vascular Biology 2004; 24: 2143–2148
   PubMed Web of Science ®Google Scholar
• Ishibashi M, Egashira K, Zhao Q, Hiasa K, Ohtani K, Ihara Y, et al. Bone marrow-derived monocyte chemoattractant protein-1 receptor CCR2 is critical in angiotensin II-induced acceleration of atherosclerosis and aneurysm formation in hypercholesterolemic mice. Arteriosclerosis & Thrombosis Vascular Biology 2004; 24: e174–e178
   PubMed Web of Science ®Google Scholar
• Charrier S, Michaud A, Badaoui S, Giroux S, Ezan E, Sainteny F, et al. Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells. Blood 2004; 104: 978–985
   PubMed Web of Science ®Google Scholar
• Haznedaroglu I C, Arici M, Buyukasik Y. A unifying hypothesis for the renin-angiotensin system and hematopoiesis: sticking the pieces together with the JAK-STAT pathway. Medical Hypotheses 2000; 54: 80–83
   PubMed Web of Science ®Google Scholar
• Rodgers K E, Xiong S, diZerega G S. Accelerated recovery from irradiation injury by angiotensin peptides. Cancer Chemotherapy & Pharmacology 2002; 49: 403–411
   PubMed Web of Science ®Google Scholar
• Ellefson D D, diZerega G S, Espinoza T, Roda N, Maldonado S, Rodgers K E. Synergistic effects of co-administration of angiotensin 1–7 and Neupogen on hematopoietic recovery in mice. Cancer Chemotherapy & Pharmacology 2004; 53: 15–24
   PubMed Web of Science ®Google Scholar
• Haznedaroglu I C. Postrenal transplant erythrocytosis, ACE inhibitors and a hypothetical local renin-angiotensin system in the bone marrow. Clinical Nephrology 1997; 48: 60
   PubMed Web of Science ®Google Scholar
• Haznedaroglu I C, Buyukasik Y. Current evidence for the existence of a local renin-angiotensin system affecting physiological and pathological haemopoiesis in the bone marrow. British Journal of Haematology 1997; 99: 471
   PubMed Web of Science ®Google Scholar
• Leung P S. The peptide hormone angiotensin II: its new functions in tissues and organs. Current Protein Peptide Science 2004; 5: 267–273
   PubMed Web of Science ®Google Scholar
• Defard M, Lemoine F M, Bonnet M L, Baillou C, Isnard F, Najman A, et al. Comparison of the effects of AcSDKP, thymosin beta4, macrophage inflammatory protein 1alpha and transforming growth factor beta on human leukemic cells. Leukemia & Lymphoma 1997; 27: 487–494
   PubMed Web of Science ®Google Scholar
• Wdzieczak-Bakala J, Grillon C, Robinson S, Riches A, Carde P, Lenfant M. Catabolism of the tetrapeptide N-Ac-Ser-Asp-Lys-Pro (AcSDKP), an inhibitor of hematopoietic stem cell (CFU-S) proliferation, following in vitro incubation with hematopoietic tissues from normal and leukemic mice. Bulletin of Cancer 1993; 80: 391–396
   PubMed Web of Science ®Google Scholar
• Comte L, Lorgeot V, Bignon J, Volkov L, Dupuis F, Wdzieczak-Bakala J, et al. In vivo modifications of AcSDKP metabolism and haematopoiesis in mice treated with 5-fluorouracil and Goralatide. European Journal of Clinical Investigations 1998; 28: 856–863
   PubMed Web of Science ®Google Scholar
• Chisi J E, Briscoe C V, Ezan E, Genet R, Riches A C, Wdzieczak-Bakala J. Captopril inhibits in vitro and in vivo the proliferation of primitive haematopoietic cells induced into cell cycle by cytotoxic drug administration or irradiation but has no effect on myeloid leukaemia cell proliferation. British Journal of Haematology 2000; 109: 563–570
   PubMed Web of Science ®Google Scholar
• Chisi J E, Wdzieczak-Bakala J, Thierry J, Briscoe C V, Riches A C. Captopril inhibits the proliferation of hematopoietic stem and progenitor cells in murine long-term bone marrow cultures. Stem Cells 1999; 17: 339–344
   PubMed Web of Science ®Google Scholar
• Wierenga P K, Konings A W. Goralatide (AcSDKP) selectively protects murine hematopoietic progenitors and stem cells against hyperthermic damage. Experimental Hematology 1996; 24: 246–252
   PubMed Web of Science ®Google Scholar
• Wierenga P K, Konings A W. Seraspenide (AcSDKP) mediated protection of hematopoietic stem cells in a hyperthermic purging protocol. Progress in Clinical Biology Research 1994; 389: 189–195
   PubMedGoogle Scholar
• Najman A, Bonnet D, Isnard F, Lemoine F, Guigon M. [Effects of the tetrapeptide AcSDKP on normal and leukemic bone marrow]. Nouvelle Revue Française D'hematologie 1993; 35: 279–280
   PubMedGoogle Scholar
• Liozon E, Pradelles P, Venot J, Rigaud M, Cransac M, Bordessoule D, et al. Serum levels of a negative regulator of cell proliferation (AcSDKP) are increased in certain human haemopathies. Leukemia 1993; 7: 808–812
   PubMed Web of Science ®Google Scholar
• Bonnet D, Cesaire R, Lemoine F, Aoudjhane M, Najman A, Guigon M. The tetrapeptide AcSDKP, an inhibitor of the cell-cycle status for normal human hematopoietic progenitors, has no effect on leukemic cells. Experimental Hematology 1992; 20: 251–255
   PubMed Web of Science ®Google Scholar
• Wierenga P K, Setroikromo R, Vellenga E, Kampinga H H. Purging of acute myeloid leukaemia cells from stem cell grafts by hyperthermia: enhancement of the therapeutic index by the tetrapeptide AcSDKP and the alkyl-lysophospholipid ET-18-OCH(3). British Journal of Haematology 2000; 111: 1145–1152
   PubMed Web of Science ®Google Scholar
• Liozon E, Volkov L, Comte L, Trimoreau F, Pradelles P, Bordessoule D. AcSDKP serum concentrations vary during chemotherapy in patients with acute myeloid leukaemia. British Journal of Haematology 1995; 89: 917–920
   PubMed Web of Science ®Google Scholar
• Caires A C, Oliveira C R, Smith M C, Hemerly J P, Juliano M A, Bincoletto C. Effects of palladacycle complex on hematopoietic progenitor cells proliferation in vivo and in vitro and its relation with the inhibitory properties of this compound on the angiotensin-I converting enzyme activity. Immunopharmacology & Immunotoxicology 2004; 26: 487–500
   PubMed Web of Science ®Google Scholar
• Bonnet D. Normal and leukaemic stem cells. British Journal of Haematology 2005; 130: 469–479
   PubMed Web of Science ®Google Scholar
• Wang J Y, Baltimore D. Localization of tyrosine kinase-coding region in v-abl oncogene by the expression of v-abl-encoded proteins in bacteria. Journal of Biological Chemistry 1985; 260: 64–71
   PubMed Web of Science ®Google Scholar
• Ernould A P, Ferry G, Barret J M, Genton A, Boutin J A. Purification and characterization of the major tyrosine protein kinase from the human promyelocytic cell line, HL60. European Journal of Biochemistry 1993; 214: 503–514
   PubMedGoogle Scholar
• Rocken C, Lendeckel U, Dierkes J, Westphal S, Carl-McGrath S, Peters B. The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion/deletion polymorphism. Clinical Cancer Research 2005; 11: 2526–2530
   PubMed Web of Science ®Google Scholar